Leonard Sanders, MD
Endocrinology, Diabetes & Metabolism · Monterey, CANPI 1336160613
Payments from drug & device makers
Across 117 payments — averaging $155.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$15K
- Insulet Corporation$1K
- Abbott$388
- BETA Bionics, Inc.$380
- AstraZeneca$211
- Lilly USA, LLC$174
- plus $654 from 11 others
What the payments were for
- Speaking & faculty fees$10,50058%
- Travel & lodging$4,45125%
- Food & beverage$3,15017%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $15,171 |
| Insulet Corporation | 43 | $1,158 |
| Abbott | 14 | $388 |
| BETA Bionics, Inc. | 5 | $380 |
| AstraZeneca(2 entities) | 4 | $211 |
| Lilly USA, LLC | 5 | $174 |
| Amgen | 7 | $169 |
| Tandem Diabetes Care, Inc. | 4 | $131 |
| Medtronic(2 entities) | 5 | $85 |
| Dexcom, Inc. | 4 | $82 |
| Novo Nordisk | 2 | $43 |
| Sanofi-aventis U.S. LLC | 1 | $31 |
| Bigfoot Biomedical Inc | 1 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Mannkind Corporation | 1 | $23 |
| Bayer | 1 | $22 |
| Radius Health, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$14,965
- iLet Bionic Pancreas$847
- FREESTYLE LIBRE 3$160
- FARXIGA$104
How this compares
$18,136 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 319 | $427,384 |
| TrulicityDulaglutide | 250 | $291,022 |
| JardianceEmpagliflozin | 182 | $268,619 |
| OzempicSemaglutide | 45 | $50,172 |
| TymlosAbaloparatide | 13 | $33,750 |
| Repatha SureclickEvolocumab | 31 | $27,865 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $23,002 |
| ProliaDenosumab | 12 | $19,740 |
| JanuviaSitagliptin Phosphate | 18 | $19,186 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 19 | $17,832 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $14,084 |
| TradjentaLinagliptin | 12 | $13,787 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $12,606 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 58 | $7,015 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $5,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $174 | $718,406569 claims |
| Novo NordiskOzempic | $43 | $50,17245 claims |
| Radius Health, Inc.Tymlos | $15 | $33,75013 claims |
| AmgenProlia | $169 | $19,74012 claims |
| MerckJanuvia | $15,171 | $19,18618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Monterey
- James ChuMonterey$1.1M
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.